DocGo Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DCGO research report →
Range $1.5 – $11
Price Chart
About the company
DocGo Inc. is a company dedicated to providing mobile healthcare solutions and medical transportation for a wide array of healthcare organizations in both the United States and the United Kingdom. Their transportation portfolio includes critical emergency response, alongside routine non-emergency transfers facilitated by ambulance and specialized wheelchair-accessible vehicles.
- CEO
- Lee Bienstock
- IPO
- 2020
- Employees
- 3,568
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on DCGO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $17.32M
- P/E
- -0.09
- PEG
- 0.00
- P/S
- 0.06
- P/B
- 0.16
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
- Gross Margin
- 31.99%
- Op Margin
- -29.04%
- Net Margin
- -60.96%
- ROE
- -144.87%
- ROIC
- -83.35%
Latest fiscal year · YoY change
- Revenue
- $322.20M-47.7%
- Gross Profit
- $98.76M-53.8%
- Op Income
- $-89,157,159
- Net Income
- $-182,399,628-1012.4%
- EPS
- $-1.84-1020.0%
- OCF Growth
- -51.0%
- FCF Growth
- -58.1%
- 52W High
- $1.10
- 52W Low
- $0.17
- 50D MA
- $0.29
- 200D MA
- $0.53
- Beta
- 1.00
- RSI (14)
- 29
- Avg Volume
- 729.51K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
DocGo delivered a smaller adjusted EBITDA loss and better gross margin in Q3, but trimmed full-year revenue guidance as it prunes unprofitable businesses and prepares for a CEO transition.· November 9, 2026
- Q3 revenue was $73.4 million, up 4% year over year, and adjusted EBITDA loss improved to $3.2 million from $7.2 million last year.
- Adjusted gross margin rose to 33.3% from 30.5% in Q2, helped by better operations despite fuel pressure and weak Upstate New York results.
- Management cut 2026 revenue guidance to about $300 million from $305 million-$310 million, while reaffirming a $17 million-$22 million adjusted EBITDA loss.
- The company is winding down the Upstate New York transport business and restructuring some Care in the Home and other low-return contracts.
- Lee Bienstock announced he will transition out as CEO after a successor is named, with an orderly handoff expected through at least March 31, 2027.
DocGo reported third-quarter 2026 revenue of $73.4 million, up 4% from $70.8 million a year ago. Adjusted EBITDA was a loss of $3.2 million versus a loss of $7.2 million in Q3 2025. Adjusted gross margin was 33.3%, compared with 33.0% in Q3 2025 and 30.5% in Q2 2026. For the full year, management now expects revenue of approximately $300 million, down from prior guidance of $305 million-$310 million, and continues to expect adjusted EBITDA loss of $17 million-$22 million. Management said the revenue revision reflects discontinuing or restructuring unprofitable business lines, including the Upstate New York medical transportation business, which it said generates about $10 million in annual revenue and will reduce 2026 adjusted EBITDA by about $3 million but not recur in 2027.
Lee Bienstock framed the quarter as proof that the business is moving toward profitability and cash flow, saying the company is making a deliberate tradeoff of some revenue for better economics. He highlighted the pivot from emergency response toward a vertically integrated hybrid care model combining transport, virtual care, in-person care, and technology, and said the foundation is now in place. His tone was upbeat but reflective, especially as he announced his planned CEO transition and said he remains focused on profitability through the handoff.
Norman Rosenberg emphasized that the quarter delivered the company’s first year-over-year revenue increase since Q2 2023, and he pointed to segment mix and portfolio pruning as the main drivers of the updated outlook. He detailed improving economics: transport adjusted gross margin was 34.7%, overtime fell to near 10%, SG&A declined to $28.7 million, and cash at September 30 was $19.1 million versus $25.2 million at June 30. He also highlighted the $12.5 million Perceptive debt tranche closed on October 1, another $12.5 million available when Hicuity closes, and ongoing progress on roughly $19 million of receivables, with about $6.7 million expected imminently.
Analysts focused on the 2027 outlook, the CEO transition, the fourth-quarter revenue bridge, and how much of the business would need to be reworked to reach profitability. Management said it did not issue 2027 guidance, but expects solid year-over-year revenue growth and positive adjusted EBITDA in 2027, with more emphasis on portfolio management and margin quality. They also said Q4 should benefit from seasonality in SteadyMD and Care in the Home, while the CEO search will prioritize someone with restructuring/turnaround experience. On Hicuity, management said the deal is not slipping and remains on track to close later this month or early next month.
The call showed visible operating leverage: revenue was flat sequentially, but gross margin, SG&A, and adjusted EBITDA all improved, and management said the company is nearing its internal break-even model. Management also believes the remaining portfolio can support growth, citing stronger transport demand in key markets, higher seasonality ahead in Q4, and a path for Care in the Home, SteadyMD, and Hicuity to contribute more in 2027.
The company still has not reached profitability, and it lowered revenue guidance because it is exiting or shrinking business lines that did not meet return thresholds. Fuel costs, weak legacy markets like Upstate New York, and lower Care in the Home volume all remain headwinds, and management acknowledged some contracts and markets are still not economically attractive. The CEO transition also adds execution risk even as the board looks for a leader with turnaround experience.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 97.2%
- Shares Outstanding
- 98.99M
- Float Shares
- 96.19M
of shares held by institutions
122 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 5.09M | ▲ 13.06K |
| Vanguard Capital Management LLC | 3.90M | ▲ 167.76K |
| P.A.W. Capital Corp | 3.75M | 0 |
| Knott David M Jr | 2.67M | 0 |
| S Squared Technology, LLC | 2.06M | 0 |
| Renaissance Technologies LLC | 1.97M | ▼ 284.00K |
| Acadian Asset Management LLC | 1.74M | ▼ 48.46K |
| Moore Capital Management, LP | 1.47M | 0 |
| Gsa Capital Partners Llp | 1.44M | ▲ 438.75K |
| Blackrock, Inc. | 1.39M | ▼ 60.31K |
| Geode Capital Management, LLC | 1.05M | ▼ 14.26K |
| Aqr Capital Management LLC | 614.73K | ▼ 1.09M |
Held by 36 ETFs
Biggest fund positions in DCGO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Bienstock Lee | other | 15,644 |
| Mar 30, 26 | Bienstock Lee | other | 18,811 |
| Dec 12, 25 | Bienstock Lee | other | 1,113,495 |
| Dec 15, 25 | Bienstock Lee | other | 214,131 |
| Dec 12, 25 | ROSENBERG NORMAN | other | 429,405 |
| Dec 15, 25 | ROSENBERG NORMAN | other | 65,774 |
| Dec 12, 25 | Sugrue Stephen | other | 321,055 |
| Dec 15, 25 | Sugrue Stephen | other | 35,968 |
| Dec 12, 25 | Tendler Ely D | other | 100,000 |
| Dec 15, 25 | Tendler Ely D | sell | 16,850 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DCGO coverage
Recent articles, reports, and earnings notes.
No research on DCGO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DCGO report →DocGo Inc. (DCGO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
DocGo Inc. (DCGO) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 9
DocGo Announces Third Quarter 2026 Results and CEO Transition
businesswire.com · Nov 9
DocGo to Announce Third Quarter 2026 Results on Monday, November 9, 2026
businesswire.com · Nov 3
DocGo Inc. (NASDAQ:DCGO) Stock Has Average Target Price of $2.38
defenseworld.net · Oct 21
Lumexa Imaging (NASDAQ:LMRI) versus DocGo (NASDAQ:DCGO) Head-To-Head Comparison
defenseworld.net · Oct 7
DocGo Eyes Connected Care Platform With Hicuity Health Acquisition
defenseworld.net · Oct 5
DocGo Inc. (DCGO) Discusses Pending Acquisition of Hicuity Health and Related Financial Projections Transcript
seekingalpha.com · Sep 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.